XML 80 R48.htm IDEA: XBRL DOCUMENT
v3.20.4

Segments (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2020
Segment Reporting [Abstract] |
Information by Reportable Segment | Information by reportable segment was as follows:
| PGEN Therapeutics |  | ActoBio |  |  |  | Trans Ova |  | Human Biotherapeutics |  | All Other |  | Total
Goodwill |  |  |  |  |  |  |  |  |  |  |  |  |
Balances at December 31, 2018 | $ | 15,232 |  |  | $ | 1,788 |  |  |  |  | $ | 46,236 |  |  | $ | — |  |  | $ | 20,736 |  |  | $ | 83,992 |
Reallocations from changes to reporting units | — |  |  | — |  |  |  |  | — |  |  | 482 |  |  | (482) |  |  | — |
Impairments | — |  |  | — |  |  |  |  | (29,642) |  |  | — |  |  | (178) |  |  | (29,820) |
Foreign currency translation adjustments | — |  |  | (53) |  |  |  |  | — |  |  | — |  |  | — |  |  | (53) |
Balances at December 31, 2019 | 15,232 |  |  | 1,735 |  |  |  |  | 16,594 |  |  | 482 |  |  | 20,076 |  |  | 54,119 |
Foreign currency translation adjustments | — |  |  | 244 |  |  |  |  | — |  |  | — |  |  | — |  |  | 244 |
Balances at December 31, 2020 | $ | 15,232 |  |  | $ | 1,979 |  |  |  |  | $ | 16,594 |  |  | $ | 482 |  |  | $ | 20,076 |  |  | $ | 54,363 |
| Year Ended December 31, 2020
| PGEN Therapeutics |  | ActoBio |  |  |  | Trans Ova |  | Human Biotherapeutics |  | All Other |  | Total
Revenues from external customers | $ | 776 |  |  | $ | 3,053 |  |  |  |  | $ | 71,186 |  |  | $ | 17,810 |  |  | $ | 10,299 |  |  | $ | 103,124 |
Intersegment revenues | 5,006 |  |  | (3) |  |  |  |  | 340 |  |  | — |  |  | 281 |  |  | 5,624 |
Total segment revenues | $ | 5,782 |  |  | $ | 3,050 |  |  |  |  | $ | 71,526 |  |  | $ | 17,810 |  |  | $ | 10,580 |  |  | $ | 108,748 |
Segment Adjusted EBITDA | $ | (25,611) |  |  | $ | (7,861) |  |  |  |  | $ | 2,624 |  |  | $ | (2,139) |  |  | $ | 4,274 |  |  | $ | (28,713) |
| Year Ended December 31, 2019
| PGEN Therapeutics |  | ActoBio |  |  |  | Trans Ova |  | Human Biotherapeutics |  | All Other |  | Total
Revenues from external customers | $ | 2,227 |  |  | $ | (364) |  |  |  |  | $ | 68,672 |  |  | $ | 3,713 |  |  | $ | 12,514 |  |  | $ | 86,762 |
Intersegment revenues | 11,341 |  |  | 498 |  |  |  |  | 1,361 |  |  | — |  |  | 1,270 |  |  | 14,470 |
Total segment revenues | $ | 13,568 |  |  | $ | 134 |  |  |  |  | $ | 70,033 |  |  | $ | 3,713 |  |  | $ | 13,784 |  |  | $ | 101,232 |
Segment Adjusted EBITDA | $ | (30,164) |  |  | $ | (13,662) |  |  |  |  | $ | (6,337) |  |  | $ | (1,051) |  |  | $ | (4,901) |  |  | $ | (56,115) |
| Year Ended December 31, 2018
| PGEN Therapeutics |  | ActoBio |  |  |  | Trans Ova |  | Human Biotherapeutics |  | All Other |  | Total
Revenues from external customers | $ | 29,021 |  |  | $ | 6,684 |  |  |  |  | $ | 75,178 |  |  | $ | — |  |  | $ | 30,213 |  |  | $ | 141,096 |
Intersegment revenues | 617 |  |  | 840 |  |  |  |  | 558 |  |  | — |  |  | 255 |  |  | 2,270 |
Total segment revenues | $ | 29,638 |  |  | $ | 7,524 |  |  |  |  | $ | 75,736 |  |  | $ | — |  |  | $ | 30,468 |  |  | $ | 143,366 |
Segment Adjusted EBITDA | $ | (32,832) |  |  | $ | (12,797) |  |  |  |  | $ | (5,730) |  |  | $ | — |  |  | $ | (10,708) |  |  | $ | (62,067) |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated | The table below reconciles total segment revenues from reportable segments to total consolidated revenues:
| Year Ended December 31,
| 2020 |  | 2019 |  | 2018
Total segment revenues from reportable segments | $ | 98,168 |  |  | $ | 87,448 |  |  | $ | 112,898 |
Other revenues, including from other operating segments | 10,634 |  |  | 17,964 |  |  | 40,841 |
Elimination of intersegment revenues | (5,624) |  |  | (14,690) |  |  | (2,561) |
Total consolidated revenues | $ | 103,178 |  |  | $ | 90,722 |  |  | $ | 151,178 |
The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continuing operations before income taxes:
| Year Ended December 31,
| 2020 |  | 2019 |  | 2018
Segment Adjusted EBITDA for reportable segments | $ | (32,987) |  |  | $ | (51,214) |  |  | $ | (51,359) |
All Other Segment Adjusted EBITDA | 4,274 |  |  | (4,901) |  |  | (10,708) |
Remove cash paid for capital expenditures and investments in affiliates | 6,970 |  |  | 12,512 |  |  | 15,276 |
Add recognition of previously deferred revenue associated with upfront and milestone payments | 25,005 |  |  | 14,721 |  |  | 33,204 |
Other expenses: |  |  |  |  |
Interest expense | (18,400) |  |  | (17,666) |  |  | (8,473) |
Depreciation and amortization | (15,042) |  |  | (16,142) |  |  | (20,612) |
Impairment losses | (920) |  |  | (30,810) |  |  | — |
Reacquisition of in-process research and development | — |  |  | — |  |  | (236,748) |
Loss on settlement agreement | (11,436) |  |  | — |  |  | — |
Stock-based compensation expense | (19,746) |  |  | (15,098) |  |  | (30,554) |
Adjustment related to accrued bonuses paid in equity awards | 2,833 |  |  | — |  |  | — |
Equity in net loss of affiliates | (1,138) |  |  | (2,416) |  |  | (8,986) |
Other | 11 |  |  | 67 |  |  | — |
Unallocated corporate costs | (37,566) |  |  | (46,011) |  |  | (74,609) |
Eliminations | (5,713) |  |  | (14,306) |  |  | (2,343) |
Consolidated net loss from continuing operations before income taxes | $ | (103,855) |  |  | $ | (171,264) |  |  | $ | (395,912) |

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration